| Bilgi: |
Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19
ROCHESTER, Minn. ― In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab ― two monoclonal antibody treatments under Food and Drug Administration emergency use authorization ― keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine. Nearly 1,400 Mayo Clinic patients were enrolled in the study ― 696 who received the drug combo between December 2020 and early…
https://newsnetwork.mayoclinic.org/?p=316702
|
